Request for Covid-19 Impact Assessment of this Report

Diagnostic and Biotech

Global Commercializing Biomarkers in Therapeutic and Diagnostic Applications Industry 2016 Deep Market Research Report

  • QYR384926
  • 140 Pages
  • January 2016
  • Diagnostic and Biotech
Download Sample    Get Discount   
 
“Global Commercializing Biomarkers in Therapeutic and Diagnostic Applications Industry 2016 Deep Market Research Report” is an in-depth and comprehensive study on the market dynamics, key trends, growth prospects, market profile of top players, technological developments, and change in regulatory framework impact the market status. The study highlights the current and future trends, market estimations of key segments, key drivers and restraints along with detailed forecast across major regions.

The analysis is an exhaustive study tracking changes in manufacturing cost structure, covering price analysis of bill of materials, labor cost analysis, depreciation cost along with scrutiny of major manufacturing processes prominently used in major regions. The report offers raw materials analysis in terms of their sources and pricing, R&D status and technological basis of key processes along with capacity and commercial production date in 2015. The study offers detailed market data on the vital industrial parameters along the historic period as well analysis the trend along the forecast period. The major manufacturers going through the report will get useful information on import-export analysis of the major market segments across major nations.

The study explores the impact on the changes in industrial policies and the factors that are responsible for the change. Impact analysis of changes in government regulations concerning the launch of recent pharmaceutical products are covered in great detail. The analysis offers information on upstream raw material analysis and downstream client survey along with changes in industry chain structure of Commercializing Biomarkers in Therapeutic and Diagnostic Applications industry. The report offers the market adoption of major pharmaceutical products and the effect of extended timeline in major markets. The study offers an examination of some of the major chain structure implemented by key vendors and the tactical moves initiated to gain a stronghold in the market. Interested market participants and industry players along with key stakeholders would get a critical examination of competitive landscape and strategic analysis in terms of recent mergers and acquisitions, technological innovations brought about and the burning issues impacting the dynamics of the industry players.

The report on Commercializing Biomarkers in Therapeutic and Diagnostic Applications offers useful information on important projects along with investment feasibility analysis of the same. This will help the industry leaders and investors in identifying the imminent investment pockets and in effective strategy formulation.

Similar Report

Global Cancer Biomarkers Market 2015-2019

Table Of Contents

1 Industry Overview 1

1.1 Basic Information of Commercializing Biomarkers in Therapeutic and Diagnostic Applications 1

1.1.1 Definition of Commercializing Biomarkers in Therapeutic and Diagnostic Applications 1

1.1.2 Segments of Commercializing Biomarkers in Therapeutic and Diagnostic Applications 2

1.1.3 Applications of Commercializing Biomarkers in Therapeutic and Diagnostic Applications 3

1.1.4 Characteristics of Commercializing Biomarkers in Therapeutic and Diagnostic Applications 4

1.2 Development Overview of Commercializing Biomarkers in Therapeutic and Diagnostic Applications 4

1.3 Enter Barriers Analysis of Commercializing Biomarkers in Therapeutic and Diagnostic Applications 5

2 Commercializing Biomarkers in Therapeutic and Diagnostic Applications International and China Market Analysis 8

2.1 Commercializing Biomarkers in Therapeutic and Diagnostic Applications Industry International Market Analysis 8

2.1.1 Commercializing Biomarkers in Therapeutic and Diagnostic Applications International Market Development History 8

2.1.2 Commercializing Biomarkers in Therapeutic and Diagnostic Applications Competitive Landscape Analysis 9

2.1.3 Commercializing Biomarkers in Therapeutic and Diagnostic Applications International Main Regions Development Status 10

2.1.4 Commercializing Biomarkers in Therapeutic and Diagnostic Applications International Market Development Trend 11

2.2 Commercializing Biomarkers in Therapeutic and Diagnostic Applications Industry China Market Analysis 12

2.2.1 Commercializing Biomarkers in Therapeutic and Diagnostic Applications China Market Development History 12

2.2.2 Commercializing Biomarkers in Therapeutic and Diagnostic Applications China Main Regions Development Status 13

2.3 Commercializing Biomarkers in Therapeutic and Diagnostic Applications International and China Market Comparison Analysis 13

3 Environment Analysis of Commercializing Biomarkers in Therapeutic and Diagnostic Applications 14

3.1 International Economy Analysis 14

3.2 China Economy Analysis 18

3.3 Policy Analysis of Commercializing Biomarkers in Therapeutic and Diagnostic Applications 20

3.4 News Analysis of Commercializing Biomarkers in Therapeutic and Diagnostic Applications 20

4 Analysis of Revenue by Segments 22

4.1 Global Revenue of Commercializing Biomarkers in Therapeutic and Diagnostic Applications by Segments 2011-2016 22

4.2 Global Revenue Growth Rate of Commercializing Biomarkers in Therapeutic and Diagnostic Applications by Segments 2011-2016 26

4.3 Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue by Segments 27

5 Analysis of Revenue by Regions and Applications 29

5.1 Global Revenue of Commercializing Biomarkers in Therapeutic and Diagnostic Applications by Regions 2011-2016 29

5.2 2011-2016 North America Revenue and Revenue Growth Rate of Commercializing Biomarkers in Therapeutic and Diagnostic Applications 33

5.3 2011-2016 Europe Revenue and Revenue Growth Rate of Commercializing Biomarkers in Therapeutic and Diagnostic Applications 34

5.4 2011-2016 Japan Revenue and Revenue Growth Rate of Commercializing Biomarkers in Therapeutic and Diagnostic Applications 35

5.5 2011-2016 China Revenue and Revenue Growth Rate of Commercializing Biomarkers in Therapeutic and Diagnostic Applications 36

6 Analysis of Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue Market Status 2011-2016 37

6.1 Revenue of Commercializing Biomarkers in Therapeutic and Diagnostic Applications 2011-2016 37

6.2 Revenue Market Share Analysis of Commercializing Biomarkers in Therapeutic and Diagnostic Applications 2011-2016 39

6.3 Revenue Overview of Commercializing Biomarkers in Therapeutic and Diagnostic Applications 2011-2016 47

6.4 Gross Margin of Commercializing Biomarkers in Therapeutic and Diagnostic Applications 2011-2016 48

7 Analysis of Commercializing Biomarkers in Therapeutic and Diagnostic Applications Industry Key Players 52

7.1 Roche 52

7.1.1 Company Profile 52

7.1.2 Revenue and Gross Margin 53

7.1.3 Roche SWOT Analysis 53

7.2Dako (Agilent Technologies) 54

7.2.1 Company Profile 54

7.2.2 Revenue and Gross Margin 55

7.2.3 Commercializing Biomarkers in Therapeutic and Diagnostic Applications SWOT Analysis 56

7.3 Merck 56

7.3.1 Company Profile 56

7.3.2 Revenue and Gross Margin 57

7.3.3 Merck SWOT Analysis 58

7.4 BD 59

7.4.1 Company Profile 59

7.4.2 Product Picture and Specifications 60

7.1.3 Revenue and Gross Margin 60

7.4.4 Commercializing Biomarkers in Therapeutic and Diagnostic Applications SWOT Analysis 61

7.5 Abbott 62

7.5.1 Company Profile 62

7.5.2 Product Picture and Specifications 63

7.5.3 Revenue and Gross Margin 63

7.5.4 Commercializing Biomarkers in Therapeutic and Diagnostic Applications SWOT Analysis 64

7.6 Genesys Biolabs (20/20GeneSystems) 65

7.6.1 Company Profile 65

7.6.2 Revenue and Gross Margin 66

7.6.3 Commercializing Biomarkers in Therapeutic and Diagnostic Applications SWOT Analysis 67

7.7 Affymetrix 67

7.7.1 Company Profile 67

7.7.2 Product Picture and Specifications 68

7.7.3 Revenue and Gross Margin 69

7.7.4 Commercializing Biomarkers in Therapeutic and Diagnostic Applications SWOT Analysis 70

7.8 Agendia 71

7.8.1 Company Profile 71

7.8.2 Product Picture and Specifications 72

7.8.3 Revenue and Gross Margin 73

7.8.4 Commercializing Biomarkers in Therapeutic and Diagnostic Applications SWOT Analysis 74

7.9 ALMAC 74

7.9.1 Company Profile 74

7.9.2 Revenue and Gross Margin 75

7.9.3 Commercializing Biomarkers in Therapeutic and Diagnostic Applications SWOT Analysis 76

7.10 Arrayit 77

7.10.1 Company Profile 77

7.10.2 Revenue and Gross Margin 78

7.10.3 Commercializing Biomarkers in Therapeutic and Diagnostic Applications SWOT Analysis 79

7.11 Biocartic 79

7.11.1 Company Profile 79

7.11.2 Product Picture and Specifications 80

7.11.3 Revenue and Gross Margin 81

7.11.4 Commercializing Biomarkers in Therapeutic and Diagnostic Applications SWOT Analysis 82

7.12 BG Medicine 82

7.12.1 Company Profile 82

7.12.2 Product Picture and Specifications 83

7.12.3 Revenue and Gross Margin 83

7.12.4 Commercializing Biomarkers in Therapeutic and Diagnostic Applications SWOT Analysis 84

7.13 KEGG EXPRESSION Database 85

7.13.1 Company Profile 85

7.13.3 Revenue and Gross Margin 86

7.13.4 Commercializing Biomarkers in Therapeutic and Diagnostic Applications SWOT Analysis 87

7.14 Thermo Fisher 87

7.14.1 Company Profile 87

7.14.2 Product Picture and Specifications 88

7.14.3 Revenue and Gross Margin 88

7.14.4 Commercializing Biomarkers in Therapeutic and Diagnostic Applications SWOT Analysis 89

7.15 BGI 90

7.15.1 Company Profile 90

7.15.2 Revenue and Gross Margin 91

7.15.3 Commercializing Biomarkers in Therapeutic and Diagnostic Applications SWOT Analysis 92

8 Sales Price and Gross Margin Analysis 94

8.1 Analysis of Cost, Gross and Gross margin 94

8.1.1 Cost Analysis 94

8.2 Gross Margin Analysis 94

9 Marketing Trader or Distributor Analysis of Commercializing Biomarkers in Therapeutic and Diagnostic Applications 96

9.1 Marketing Channels Status of Commercializing Biomarkers in Therapeutic and Diagnostic Applications 96

9.2 Business Model of Commercializing Biomarkers Service Supplier 97

10 Development Trend of Commercializing Biomarkers in Therapeutic and Diagnostic Applications Industry 2016-2021 98

10.1 Revenue Overview of Commercializing Biomarkers in Therapeutic and Diagnostic Applications 2016-2021 98

10.2 Gross Margin Overview of Commercializing Biomarkers in Therapeutic and Diagnostic Applications 2016-2021 100

11 Industry Chain Suppliers of Commercializing Biomarkers in Therapeutic and Diagnostic Applications with Contact Information 101

11.1 Equipment Suppliers of Commercializing Biomarkers in Therapeutic and Diagnostic Applications with Contact Information 101

11.2 Major Suppliers of Commercializing Biomarkers in Therapeutic and Diagnostic Applications with Contact Information 101

11.3 Key Consumers of Commercializing Biomarkers in Therapeutic and Diagnostic Applications with Contact Information 102

11.4 Supply Chain Relationship Analysis of Commercializing Biomarkers in Therapeutic and Diagnostic Applications 103

12 New Project SWOT Analysis of Commercializing Biomarkers in Therapeutic and Diagnostic Applications 105

13 Conclusion of the Global Commercializing Biomarkers in Therapeutic and Diagnostic Applications Industry 2016 106


List Of Tables and Figures

Figure some techniques of biological markers for research 2

Table Segments of Commercializing Biomarkers in Therapeutic and Diagnostic Applications 2

Table, the characteristics of biomarkers and related industry 4

Table Global Major Commercializing Biomarkers in Therapeutic and Diagnostic Applications Players 5

Figure Commercializing Biomarkers in Therapeutic and Diagnostic Applications Development History 8

Figure Global Revenue of Commercializing Biomarkers in Therapeutic and Diagnostic Applications 2011-2016 9

Figure Global Major Player Revenue Market Share of Commercializing Biomarkers in Therapeutic and Diagnostic Applications 2015 10

Figure Global Main Regions Revenue Market Share of Commercializing Biomarkers in Therapeutic and Diagnostic Applications 2015 11

Figure Pre-competitive collaboration can help expand published shared knowledge 11

Figure China Revenue of Commercializing Biomarkers in Therapeutic and Diagnostic Applications 2015 12

Table China Main Regions Development Status 13

Figure Global & China Revenue of Commercializing Biomarkers in Therapeutic and Diagnostic Applications 2011-2016 13

Figure Global GDP Map 2014 14

Figure USA GDP Change 2005-2014 15

Figure USA CPI Change 2011-2015 15

Figure EU GDP Change 2005-2014 16

Figure German CPI Change 2011-2015 16

Figure UK CPI Change 2011-2015 17

Figure Japan GDP Change 2005-2014 17

Figure Japan CPI Change 2005-2014 18

Figure China GDP Change 2005-2014 18

Figure China CPI Change 2005-2014 19

Figure China PPI Growth Rate 2005-2014 19

Table Policy of Commercializing Biomarkers in Therapeutic and Diagnostic Applications 20

Table Industry News 1 of Commercializing Biomarkers in Therapeutic and Diagnostic Applications 20

Table Global Revenue of Commercializing Biomarkers in Therapeutic and Diagnostic Applications by Segments 2011-2016 (M USD) 22

Table Global Revenue Market Share of Commercializing Biomarkers in Therapeutic and Diagnostic Applications by Segments 2011-2016 22

Figure Global Revenue Market Share of Commercializing Biomarkers in Therapeutic and Diagnostic Applications by Segments in 2011 23

Figure Global Revenue Market Share of Commercializing Biomarkers in Therapeutic and Diagnostic Applications by Segments in 2012 23

Figure Global Revenue Market Share of Commercializing Biomarkers in Therapeutic and Diagnostic Applications by Segments in 2013 24

Figure Global Revenue Market Share of Commercializing Biomarkers in Therapeutic and Diagnostic Applications by Segments in 2014 24

Figure Global Revenue Market Share of Commercializing Biomarkers in Therapeutic and Diagnostic Applications by Segments in 2015 25

Figure Global Revenue Market Share of Commercializing Biomarkers in Therapeutic and Diagnostic Applications by Segments in 2016 25

Figure Global Revenue Growth Rate of Consumables 2011-2016 26

Figure Global Revenue Growth Rate of Services 2011-2016 26

Figure Global Revenue Growth Rate of Software 2011-2016 27

Table North America Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue by Segments 27

Table Europe Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue by Segments 27

Table Japan Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue by Segments 27

Table China Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue by Segments 28

Table Global Revenue of Commercializing Biomarkers in Therapeutic and Diagnostic Applications by Regions 2011-2016 (M USD) 29

Table Global Revenue Market Share of Commercializing Biomarkers in Therapeutic and Diagnostic Applications by Regions 2011-2016 29

Figure Global Revenue Market Share of Commercializing Biomarkers in Therapeutic and Diagnostic Applications by Regions in 2011 30

Figure Global Revenue Market Share of Commercializing Biomarkers in Therapeutic and Diagnostic Applications by Regions in 2012 30

Figure Global Revenue Market Share of Commercializing Biomarkers in Therapeutic and Diagnostic Applications by Regions in 2013 31

Figure Global Revenue Market Share of Commercializing Biomarkers in Therapeutic and Diagnostic Applications by Regions in 2014 31

Figure Global Revenue Market Share of Commercializing Biomarkers in Therapeutic and Diagnostic Applications by Regions in 2015 32

Figure Global Revenue Market Share of Commercializing Biomarkers in Therapeutic and Diagnostic Applications by Regions in 2016 32

Table North America Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue by Applications 33

Figure North America Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue and Revenue Growth Rate 33

Table Europe Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue by Applications 34

Figure Europe Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue and Revenue Growth Rate 34

Table Japan Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue by Applications 35

Figure Japan Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue and Revenue Growth Rate 35

Table China Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue by Applications 36

Figure China Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue and Revenue Growth Rate 36

Table Global and China Major Players Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue of 2011-2016 (M USD) 37

Table Global and China Major Players Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue Market Share of 2011-2016 37

Table China Major Players Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue of 2011-2016 (M USD) 38

Table China Major Players Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue Market Share of 2011-2016 38

Figure Global Revenue Market Share of Major Commercializing Biomarkers in Therapeutic and Diagnostic Applications Players in 2011 39

Figure Global Revenue Market Share of Major Commercializing Biomarkers in Therapeutic and Diagnostic Applications Players in 2012 40

Figure Global Revenue Market Share of Major Commercializing Biomarkers in Therapeutic and Diagnostic Applications Players in 2013 41

Figure Global Revenue Market Share of Major Commercializing Biomarkers in Therapeutic and Diagnostic Applications Players in 2014 42

Figure Global Revenue Market Share of Major Commercializing Biomarkers in Therapeutic and Diagnostic Applications Players in 2015 43

Figure Global Revenue Market Share of Major Commercializing Biomarkers in Therapeutic and Diagnostic Applications Players in 2016 44

Figure China Revenue Market Share Major Commercializing Biomarkers in Therapeutic and Diagnostic Applications Players in 2011 44

Figure China Revenue Market Share Major Commercializing Biomarkers in Therapeutic and Diagnostic Applications Players in 2012 45

Figure China Revenue Market Share Major Commercializing Biomarkers in Therapeutic and Diagnostic Applications Players in 2013 45

Figure China Revenue Market Share Major Commercializing Biomarkers in Therapeutic and Diagnostic Applications Players in 2014 46

Figure China Revenue Market Share Major Commercializing Biomarkers in Therapeutic and Diagnostic Applications Players in 2015 46

Figure China Revenue Market Share Major Commercializing Biomarkers in Therapeutic and Diagnostic Applications Players in 2016 47

Figure Global Revenue and Growth Rate of Commercializing Biomarkers in Therapeutic and Diagnostic Applications 2011-2016 47

Figure China Revenue and Growth Rate of Commercializing Biomarkers in Therapeutic and Diagnostic Applications 2011-2016 48

Figure 2011-2016 Global and China Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue Comparison 48

Table Cost of Global Commercializing Biomarkers in Therapeutic and Diagnostic Applications Major Players 2011-2016 (M USD) 48

Table Gross of Global Commercializing Biomarkers in Therapeutic and Diagnostic Applications Major Players 2011-2016 (M USD) 49

Table Gross Margin of Global Commercializing Biomarkers in Therapeutic and Diagnostic Applications Major Players 2011-2016 50

Figure Gross Margin of Global Commercializing Biomarkers in Therapeutic and Diagnostic Applications Major Players in 2014 51

Table Roche Company Profile List 52

Table Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue, Cost, Gross (M USD) Revenue Growth Rate and Gross Margin of Roche 2011-2016 53

Figure Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue and Growth Rate of Roche 2011-2016 53

Table Roche Commercializing Biomarkers in Therapeutic and Diagnostic Applications SWOT Analysis 53

Table Dako (Agilent Technologies) Information List 54

Table Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue, Cost, Gross (M USD) Revenue Growth Rate and Gross Margin of Commercializing Biomarkers in Therapeutic and Diagnostic Applications 2011-2016 55

Figure Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue and Growth Rate of Commercializing Biomarkers in Therapeutic and Diagnostic Applications 2011-2016 55

Table Commercializing Biomarkers in Therapeutic and Diagnostic Applications Commercializing Biomarkers in Therapeutic and Diagnostic Applications SWOT Analysis 56

Table Merck Company Profile List 56

Table Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue, Cost, Gross (M USD) Revenue Growth Rate and Gross Margin of Merck 2011-2016 57

Figure Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue and Growth Rate of Merck 2011-2016 58

Table Merck Commercializing Biomarkers in Therapeutic and Diagnostic Applications SWOT Analysis 58

Table BD Information List 59

Figure Commercializing Biomarkers in Therapeutic and Diagnostic Applications Picture and Specifications of BD 60

Table Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue, Cost, Gross (M USD) Revenue Growth Rate and Gross Margin of Commercializing Biomarkers in Therapeutic and Diagnostic Applications 2011-2016 60

Figure Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue and Growth Rate of Commercializing Biomarkers in Therapeutic and Diagnostic Applications 2011-2016 61

Table Commercializing Biomarkers in Therapeutic and Diagnostic Applications Commercializing Biomarkers in Therapeutic and Diagnostic Applications SWOT Analysis 61

Table Abbott Information List 62

Figure Commercializing Biomarkers in Therapeutic and Diagnostic Applications Picture 63

Table Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue, Cost, Gross (M USD) Revenue Growth Rate and Gross Margin of Commercializing Biomarkers in Therapeutic and Diagnostic Applications 2011-2016 63

Figure Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue and Growth Rate of Commercializing Biomarkers in Therapeutic and Diagnostic Applications 2011-2016 64

Table Commercializing Biomarkers in Therapeutic and Diagnostic Applications Commercializing Biomarkers in Therapeutic and Diagnostic Applications SWOT Analysis 64

Table Genesys Biolabs(20/20GeneSystems) Information List 65

Table Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue, Cost, Gross (M USD) Revenue Growth Rate and Gross Margin of Commercializing Biomarkers in Therapeutic and Diagnostic Applications 2011-2016 66

Figure Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue and Growth Rate of Commercializing Biomarkers in Therapeutic and Diagnostic Applications 2011-2016 66

Table Commercializing Biomarkers in Therapeutic and Diagnostic Applications Commercializing Biomarkers in Therapeutic and Diagnostic Applications SWOT Analysis 67

Table Affymetrix Information List 67

Figure Commercializing Biomarkers in Therapeutic and Diagnostic Applications Picture and Specifications of Affymetrix 68

Table Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue, Cost, Gross (M USD) Revenue Growth Rate and Gross Margin of Commercializing Biomarkers in Therapeutic and Diagnostic Applications 2011-2016 69

Figure Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue and Growth Rate of Commercializing Biomarkers in Therapeutic and Diagnostic Applications 2011-2016 70

Table Commercializing Biomarkers in Therapeutic and Diagnostic Applications Commercializing Biomarkers in Therapeutic and Diagnostic Applications SWOT Analysis 70

Table Agendia Information List 71

Figure Commercializing Biomarkers in Therapeutic and Diagnostic Applications Picture and Specifications of Agendia 72

Table Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue, Cost, Gross (M USD) Revenue Growth Rate and Gross Margin of Commercializing Biomarkers in Therapeutic and Diagnostic Applications 2011-2016 73

Figure Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue and Growth Rate of Commercializing Biomarkers in Therapeutic and Diagnostic Applications 2011-2016 73

Table Commercializing Biomarkers in Therapeutic and Diagnostic Applications Commercializing Biomarkers in Therapeutic and Diagnostic Applications SWOT Analysis 74

Table ALMAC Information List 74

Table Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue, Cost, Gross (M USD) Revenue Growth Rate and Gross Margin of Commercializing Biomarkers in Therapeutic and Diagnostic Applications 2011-2016 75

Figure Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue and Growth Rate of Commercializing Biomarkers in Therapeutic and Diagnostic Applications 2011-2016 76

Table Commercializing Biomarkers in Therapeutic and Diagnostic Applications Commercializing Biomarkers in Therapeutic and Diagnostic Applications SWOT Analysis 76

Table Arrayit Information List 77

Table Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue, Cost, Gross (M USD) Revenue Growth Rate and Gross Margin of Commercializing Biomarkers in Therapeutic and Diagnostic Applications 2011-2016 78

Figure Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue and Growth Rate of Commercializing Biomarkers in Therapeutic and Diagnostic Applications 2011-2016 78

Table Commercializing Biomarkers in Therapeutic and Diagnostic Applications Commercializing Biomarkers in Therapeutic and Diagnostic Applications SWOT Analysis 79

Table Biocartic Information List 79

Figure Commercializing Biomarkers in Therapeutic and Diagnostic Applications Picture and Specifications of Biocartic 80

Table Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue, Cost, Gross (M USD) Revenue Growth Rate and Gross Margin of Commercializing Biomarkers in Therapeutic and Diagnostic Applications 2011-2016 81

Figure Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue and Growth Rate of Commercializing Biomarkers in Therapeutic and Diagnostic Applications 2011-2016 81

Table Commercializing Biomarkers in Therapeutic and Diagnostic Applications Commercializing Biomarkers in Therapeutic and Diagnostic Applications SWOT Analysis 82

Table BG Medicine Information List 82

Figure Commercializing Biomarkers in Therapeutic and Diagnostic Applications Picture and Specifications of BG Medicine 83

Table Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue, Cost, Gross (M USD) Revenue Growth Rate and Gross Margin of Commercializing Biomarkers in Therapeutic and Diagnostic Applications 2011-2016 83

Figure Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue and Growth Rate of Commercializing Biomarkers in Therapeutic and Diagnostic Applications 2011-2016 84

Table Commercializing Biomarkers in Therapeutic and Diagnostic Applications Commercializing Biomarkers in Therapeutic and Diagnostic Applications SWOT Analysis 84

Table KEGG EXPRESSION Database Information List 85

Table Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue, Cost, Gross (M USD) Revenue Growth Rate and Gross Margin of Commercializing Biomarkers in Therapeutic and Diagnostic Applications 2011-2016 86

Figure Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue and Growth Rate of Commercializing Biomarkers in Therapeutic and Diagnostic Applications 2011-2016 86

Table Commercializing Biomarkers in Therapeutic and Diagnostic Applications Commercializing Biomarkers in Therapeutic and Diagnostic Applications SWOT Analysis 87

Table Thermo Fisher Information List 87

Figure Commercializing Biomarkers in Therapeutic and Diagnostic Applications Picture and Specifications of Thermo Fisher 88

Table Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue, Cost, Gross (M USD) Revenue Growth Rate and Gross Margin of Commercializing Biomarkers in Therapeutic and Diagnostic Applications 2011-2016 88

Figure Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue and Growth Rate of Commercializing Biomarkers in Therapeutic and Diagnostic Applications 2011-2016 89

Table Commercializing Biomarkers in Therapeutic and Diagnostic Applications Commercializing Biomarkers in Therapeutic and Diagnostic Applications SWOT Analysis 89

Table BGI Information List 90

Table Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue, Cost, Gross (M USD) Revenue Growth Rate and Gross Margin of Commercializing Biomarkers in Therapeutic and Diagnostic Applications 2011-2016 91

Figure Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue and Growth Rate of Commercializing Biomarkers in Therapeutic and Diagnostic Applications 2011-2016 92

Table Commercializing Biomarkers in Therapeutic and Diagnostic Applications Commercializing Biomarkers in Therapeutic and Diagnostic Applications SWOT Analysis 92

Table Cost Analysis 94

Figure Commercializing Biomarkers in Therapeutic and Diagnostic Applications Manufactor Profit Model 94

Figure Marketing Channels Status of Commercializing Biomarkers in Therapeutic and Diagnostic Applications 96

Figure Business Model of Commercializing Biomarkers Service Supplier 97

Figure Global Revenue and Growth Rate of Commercializing Biomarkers in Therapeutic and Diagnostic Applications 2016-2021 98

Figure China Revenue and Growth Rate of Commercializing Biomarkers in Therapeutic and Diagnostic Applications 2016-2021 99

Figure Global and China Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue Comparison 2016-2021 99

Figure Gross Margin 2016-2021 100

Table Equipment Suppliers of Commercializing Biomarkers in Therapeutic and Diagnostic Applications with Contact Information 101

Table Major Suppliers of Commercializing Biomarkers in Therapeutic and Diagnostic Applications with Contact Information 101

Table Key Consumers of Commercializing Biomarkers in Therapeutic and Diagnostic Applications with Contact Information 102

Figure Biomarkers connect bench to bedside and create a continuous feedback loop for innovation. 103

Figure Data standards and semantics enable continuous information flow across industries. 104

Table New Project SWOT Analysis of Commercializing Biomarkers in Therapeutic and Diagnostic Applications 105

Table Pharmacogenomic Biomarkers in Drug Labeling 111

 
Purchase Options

* Taxes/Fees, If applicable will be
added during checkout. All prices in USD.

Need More Information

Similar Reports

Biomaterials Market by Type (Metallic, Polymeric, Ceramic and Natural) and Application (Cardiovascular, Dental, Orthopedic, Wound Healing, Plastic, Surgery, Ophthalmology, Tissue Engineering, Neurological Disorders and Drug-Delivery Systems) - Global Opportunity Analysis and Industry Forecast, 2014 - 2022

Biomaterials are materials of either synthetic or natural origin that are used for interaction with biological systems for medical purposes such as treating or repairing damage tissues. They are used in joint replacements, plastic surgeries, drug delivery devi...

  • Publish Date: September 1, 2016
  • $5370
DNA Sequencing Market by Product (Consumable, Instrument, and Service) Application (Biomarkers and Cancer, Diagnostics, Reproductive Health, Personalized Medicine, Forensics, and Others), Technology (Sequencing by Synthesis, Ion Semiconductor Sequencing, Sequencing by Ligation, Pyrosequencing, Single Molecule Real-time Sequencing, Chain Termination Sequencing, and Nanopore Sequencing), and End User (Academic & Government Research Institutes, Pharmaceutical Companies, Biotechnology Companies, and Hospitals & Clinics): Global Opportunity Analysis and Industry Forecast, 2017 - 2025

The global DNA sequencing market was estimated to be $6,243 million in 2017 and is projected to reach $25,470 million in 2025 growing with a CAGR of 19% from 2018 to 2025. DNA sequencing is a type of technology in which several DNA strands can be sequenced through massive parallelization. The DNA sequencing contains both Sanger’s method of sequencing and non-Sanger’s methods of sequencing. ...

  • Publish Date: May 24, 2017
  • $5370